Comparison of Regulatory Requirements for Registration of Pharmaceutical Drugs in Asean and GCC Regions

Mohit; Aakash       Deep; Gaurav       Khurana; Jagdeep       Kumar; Akshay       Monga

doi:10.2174/2213476X06666190128145525

Abstract

Background: The product registration in rest of the world is a challenging task because they are not harmonized. ASEAN and GCC regions come under semi-regulated market. These regions have somewhat harmonized their regulatory organization. The significance of an emerging market is increasing globally. It is important for pharmaceutical companies to be up-to-date with the latest regulatory development. ASEAN used ACTD format and GCC used ICH CTD format for drug product Registration. ASEAN includes a group of countries like Singapore, Philippines etc. Whereas GCC includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and UAE.

Conclusion: This review article focuses on general regulatory requirements of registration of pharmaceuticals in ASEAN and GCC region.

Keywords: Regulation, ASEAN, GCC, pharmaceutical companies, drugs, guidelines.

« Previous

Graphical Abstract

[1] 
Makrocare.com. 2018. [Cited: 10 August 2018];
Available from: https://www.makro-care.com/White Papers/se_asian_regulatory_environment_p1.pdf
[2] 
The Drug Regulatory Landscape in the ASEAN Region.
Raps.org. 2018. [Cited: 29 January 2018];
Available from: https://www.raps.org/news-and-articles/news-articles/2018/1/the-drug-regulatory-landscape-in-the-asean-region
[3] 
ASEAN: ICH. Ich.org. 2018. [Cited: 25 November
2018]; Available from: http://www.ich.org/ about/organisation-of-ich/assembly/asean.html
[4] 
Handoo S, Arora V, Khera D, Nandi P, Sahu KS. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. Int J Pharm Investig  2012; 2(3): 99-105.
[5] 
Moh.gov.sg. 2018. [Cited: 10 July 2018]; Available
from: https://www.moh.gov.sg/
[6] 
NPRA. Npra.moh.gov.my. 2018. [Cited: 12 June
2018]; Available from: http://npra. moh.gov.my/en
[7] 
Drug. Fda.moph.go.th. 2018. [Cited: 5 August 2018];
Available from:.http://www.fda.moph. go.th/sites/ fda_en/SitePages/Drug.aspx?IDitem=LawsAndRegulations
[8] 
Food and Drug Administration of the Philippines.
2018. [Cited: 12 August 2018]; Available from: https://www.fda.gov.ph/
[9] 
Indonesia National Agency of Drug and Food Control.
Pom.go.id. 2018. [Cited: 15 July 2018]; Available
from: http://www.pom.go.id/index.php/home/en
[10] 
Wu Y, Freed A, Lavrich D, et al. Strategies of bringing drug product marketing applications to meet current regulatory standards. AAPS PharmSciTech  2015; 4(16): 986-91.
[11] 
Lon CT, Tsuyuoka R, Phanouvong S, et al. Counterfeit and substandard antimalarial drugs in Cambodia. Trans R Soc Trop Med Hyg  2006; 100(11): 1019-24.
[12] 
Latt NN, Cho MS, Htun MMN, et al. Healthcare in Myanmar. Nagoya J Med Sci  2016; 78(2): 123-34.
[13] 
Makrocare.com. 2018. [Cited: 18 July 2018]; Available
from: https://www.makrocare.com/WhitePapers/ regulatory_environment_in_south_east_asia.pdf
[14] 
Badjatya KJ, Bodla R, Musyuni P. Export registration of pharmaceuticals in Rest Of World countries (ROW). J Drug Deliv Ther  2013; 3(1): 61-4.
[15] 
Pateriya S, Janodia MD, Deshpande PB, et al. Regulatory aspects of pharmaceuticals’ exports in Gulf Cooperation Council Countries. J Young Pharm  2011; 3(2): 155-62.
[16] 
Pezzola A, Sweet C. Global pharmaceutical regulation: The challenge of integration for developing states. Global Health  2016; 12(1): 1-18.
[17] 
Medical Regulatory Affairs Today. Pharmalinkconsulting.
com. 2018. [Cited: 7 March 2018]; Available
from: http://www.pharmalinkconsulting.com/blog/ blog/the-gulf-central-committee-for-drug-registration-gcc-dr
[18] 
Badjatya KJ. Overview of drug registration requirements for pharmaceuticals in emerging market. J Drug Deliv Ther  2013; 3(2): 227-32.
[19] 
Hashan H, Aljuffali I, Patel P, Walker S. The Saudi Arabia food and drug authority: An evaluation of the registration process and good review practices in Saudi Arabia in comparison with Australia, Canada and Singapore. Pharmaceut Med  2016; 30: 37-47.
[20] 
SFDA- Medical Device Marketing Authorisation System.
Mdma.sfda.gov.sa. 2018. [Cited: 15 August
2018]; Available from: https://mdma.sfda. gov.sa
[21] 
NHRA. Nhra.bh. 2018. [Cited: 6 June 2018]; Available
from: http://www.nhra.bh/SitePages/View.aspx? PageId=14
[22] 
Moh.gov.kw. 2018. [Cited: 10 May 2018]; Available
from: https://www.moh.gov.kw/en
[23] 
Sfda.gov.sa. 2018. [Cited: 9 July 2018]; Available
from: https://www.sfda.gov.sa/en/drug/drug_reg/ Regulations/The-GCC-Human-Drugs%20Submission -v2.1.pdf
[24] 
Asean.org. 2018. [Cited: 12 May 2018]; Available
from: http://www.asean.org/storage/ images/archive/ 20605.pdf
[25] 
Sravani M, Gowthami B, Prabhahar E, Rao RN. Regulatory aspects of pharmaceuticals in Gulf Co-operation Council Countries. Int J Pharm Chem Res  2017; 3(3): 397-414.
[26] 
Suthakaran R. Comparative study of regulatory requirements for the approval of generic drugs for Association of South East Asian Nation (ASEAN), Gulf Co-Operative Council (GCC) & United States Food and Drug Administration (USFDA). J Pharm Res  2014; 8(1): 59-63.

Rights & Permissions Print Cite

Article Metrics

44

11

1

DOI https://dx.doi.org/10.2174/2213476X06666190128145525	Print ISSN 2213-476X
Publisher Name Bentham Science Publisher	Online ISSN 2213-4778

Applied Clinical Research, Clinical Trials and Regulatory Affairs

Comparison of Regulatory Requirements for Registration of Pharmaceutical Drugs in Asean and GCC Regions

Abstract Play Pause

Graphical Abstract

Related Journals

Abstract